News
Viking Therapeutics initiates VANQUISH phase 3 obesity clinical programme with GLP-1/GIP agonist VK2735: San Diego Thursday, June 26, 2025, 10:00 Hrs [IST] Viking Therapeutics, In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback